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Table 1
2004-06 2006-10 2010-13 p (2004-06 vs
2010-13)
Day 0 to +30 42.1% 33.4% 13.8% 0.016
Day +31 to +100 61.9% 30.5% 12.7% <0.001
Day +101 to +180 62.4% 45.7% 19.8% 0.001
Day +181 to +365 26.3% 19.9% 5.0% <0.001
Figure 1. HCV Quantitative RNA PCR HCV viral load in peripheral blood was
monitored by quantitative PCR for HCV RNA weekly. Patient had 7 log10 titer
prior and after UCBT. Titers decreasedw2 log10 fold weekly after initiation of
treatment.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170 S163toxicity¼ 57 (30%), reduced intensity¼ 47 (24.7%); incidence
of neutrophil engraftment by day +30 was 82%, and inci-
dence of grade II-IV aGVHD was 44.2%,
For the different time periods of immune reconstitution,
the rate per 100 person months of bacterial infections
decreased as shown in table 1. Of the BBSIs for each time
period, the proportion of GPC BBSIs decreased (2004-06:56%,
2006-10:53.1%, 2010-13:39.2%, respectively), 2004-06 vs.
2010-13, p¼0.048.
GNR antibiotic resistance increased to levoﬂoxacin (4.4%
from 2004-06 to 17.2% from 2010-2013), decreased to cefe-
pime (13.3% from 2004-06 to 7.7% from 2010-13), and
remained stable to piperacillin-tazobactam (7.7% in 2004-06
to 9.1% from 2010-13). GPC antibiotic resistance to vanco-
mycin increased from 3.4% in 2004-06 to 10.5% in 2010-13.
Lastly, in our multivariate analysis RTC regimen was a
signiﬁcant risk factor for the development of piperacillin-
tazobactam resistance in GNR (OR 4.421, 95% CI 1.331-14.69,
p¼0.015). TRM was signiﬁcantly higher in BBSI patient be-
tween 2004-06 (27.9%) vs. 2010-13 (9.3%) (p¼0.03).
Discussion: Our analysis showed a decrease in BBSI rates
after CLABSI protocol was implemented at our institution
and a signiﬁcant decline in BBSI in the post-CLABSI era. The
proportion of GPC infections decreased over this time period.
However, further investigation on factors associated with
decrease in BBSI in these different time periods is ongoing.
The rise in vancomycin resistance (likely due to its wide-
spread use as empiric antibiotic choice for alloHCT patients
with fever), warrants further investigation.201
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Hepatitis C virus (HCV) infection increases the non-relapse
mortality risk after HSCT. Oral direct-acting antiviral (DAA)
drugs Simeprevir, an NS3/4A protease inhibitor, in combi-
nation with Sofosbuvir, a nucleotide analogue inhibitor of
NS5G polymerase are replacing the standard therapy of
interferon (IFN) and ribavirin (RBV). Here, we present the
ﬁrst case report of a pediatric patient with very high HCV
viral load after an UCBTwhowas treatedwith Sofosbuvir and
Simeprevir. The patient had an early virologic response (EVR)
and developed HCV-speciﬁc CD3+ T cells.
A 4 yr. old girl was referred for relapsed B-lymphoblastic
leukemia in CR3. HCV antibody was negative but nucleic acid
test was positive. HCV RNA PCR was elevated at log 7.2 (Fig1). Genotype was HCV-1a subtype with unfavorable vari-
ants for IL28BS but NS3 genotype was negative. Liver US was
normal and LFT was not signiﬁcantly elevated. Liver biopsy
was negative for ﬁbrosis and cirrhosis but demonstrated
moderate hepatitis.
Patient underwent a single 4 of 6 UCBT (10.6 x107 TNC/kg)
using TBI, ﬂudarabine and cyclophosphamide. GVHD pro-
phylaxis included cyclosporine (CSA) and mycophenolate
mofetil (MMF). Engraftment occurred on D13. Sinusoidal
obstruction syndrome (SOS) developed on D20-33 and
treatedwith deﬁbrotide. HCV treatment was initiated on D75
with Sofosbuvir and Simeprevir. Weekly PCR for HCV RNA
demonstrated w2log decrease (Fig 1) despite remaining on
CSA. Viral speciﬁc immune response to HCV was evaluated
using donor speciﬁc HLA-A restricted tetramer. The patient
was HLA-A*32:01/30:02 and received an UCB with HLA-
A*3:01/30:01. Using HLA-A*03:01 restricted tetrameter for
HCV epitope KLVALGINA, we identiﬁed HCV speciﬁc donor T
cells. CDR3 regions are being sequenced to determine
whether the T cell response is oligoclonal or polyclonal. The
availability of the new, highly effective oral DAA HCV medi-
cation allows for IFN-free therapy and will impact the
treatment for HCV after HSCT. The ability to clear the HCV
and maintain viral remission will signiﬁcantly decrease the
risk of developing cirrhosis, hepatic failure and hepatocel-
lular carcinoma.202
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Background: Despite advances in novel anti-plasma cell
therapies translating to improved outcomes, multiple
